![]() |
|
|
Vol. 60, Issue 5, 900-906, November 2001
Departments of Experimental Therapeutics (M.S., Y.L., Z.F.) and
Molecular Genetics (J.M.P., G.L.), The University of Texas M. D. Anderson Cancer Center, Houston, Texas; and ASTA Medica AG (G.B.,
T.B.), Frankfurt, Germany
In this study, the differential role of the cyclin-dependent kinase
(CDK) inhibitors p21Waf1 and p27Kip1 in cell
cycle regulation was proposed for use in screening natural or synthetic
compounds for cell cycle-dependent (particularly M phase-dependent)
antineoplastic activity. p21Waf1 or p27Kip1 was
ectopically expressed with an ecdysone-inducible mammalian expression
system in a human colon adenocarcinoma cell line. Induction of
p21Waf1 or p27Kip1 expression inhibited the
activities of CDK2 and completely arrested cells at G1
phase of the cell cycle by p27Kip1 and at G1
and G2 phases by p21Waf1. We examined the
sensitivity of these cells to several antineoplastic agents known to be
cell cycle-dependent or -independent. Substantially increased
resistance to cell cycle-dependent antineoplastic agents was found in
the cells when the expression of p21Waf1 or
p27Kip1 was induced. In contrast, only a desensitization to
cell cycle-independent antineoplastic agents was found in the cells
arrested by p21Waf1 or p27Kip1. Because
p21Waf1 induces an additional block at G2 phase
that inhibits cell entry into M phase, we further examined the
difference between p21Waf1- and p27Kip1-induced
cells in their sensitivity to D-24851, a novel M phase-dependent compound. We found that induction of p21Waf1 after exposure
of the cells to D-24851 conferred stronger resistance than did
induction of p27Kip1. Taken together, our results suggest
that the differential effect of p21Waf1 and
p27Kip1 on cell cycle regulation may be advantageous for
screening chemical libraries for novel antineoplastic candidates that
are cell cycle-dependent, and M phase-dependent in particular.
This article has been cited by other articles:
![]() |
J. Fink, K. Sanders, A. Rippl, S. Finkernagel, T. L. Beckers, and M. Schmidt Cell type dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines Mol. Cancer Ther., December 1, 2007; 6(12): 3189 - 3197. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-J. Lih, W. Wei, and S. N. Cohen Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes Genes & Dev., August 1, 2006; 20(15): 2082 - 2095. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Takahashi, F. Yamasaki, T. Sudo, H. Itamochi, S. Adachi, M. Tamamori-Adachi, and N. T. Ueno Cyclin A-associated kinase activity is needed for paclitaxel sensitivity Mol. Cancer Ther., July 1, 2005; 4(7): 1039 - 1046. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Waldman Markers of Cell Cycle-Mediated Drug Resistance And Prognosis Of Patients Receiving Preoperative Combined Modality Therapy For Rectal Cancer Ann. Surg. Oncol., November 1, 2004; 11(11): 949 - 950. [Full Text] [PDF] |
||||